Theriva Biologics Gross Profit

The latest gross profit for SYN is $0 as of March 2026. In the prior-year period, the figure was $0. That is below the Healthcare sector average of $65B. Investors often review this figure alongside Theriva Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SYN's gross profit moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Theriva Biologics's operating scale or balance-sheet position.

Against Healthcare companies, SYN currently prints $0 for gross profit, while the sector average sits near $65B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Theriva Biologics's growth, margins, and balance sheet.

A gross profit figure of $0 for SYN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting SYN's gross profit ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.